Docket No.: 022290.0122PTUS (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: You-Ping Chan et al.

Application No.: 10/516,733 Confirmation No.: 8573

Filed: October 3, 2005 Art Unit: 1654

For: POLYAMINOACIDS FUNCTIONALIZED BY Examiner: D. Lukton ALPHA TOCOPHEROL AND USES

THEREOF, PARTICULAR FOR THERAPEUTIC APPLICATIONS

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 GFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 GFR 1.98(a)(2).

WO 00/30618 and FR 2801226 are in French, but include English Language abstracts.

Applicants believe books referenced in the specification for general, conventional scientific techniques, are not relevant to the patentability of the claimed subject matter of the above-referenced application and have not listed them on form SB/08 or submitted copies, specifically, R. Arshady, ed., "Microspheres, Microcapsules and Liposomes: Vol. 1 Preparation and Chemical Applications," <u>Cirus Books</u>, 1999, J. Senior et al., ed., "Sustained-Release Injectable Products," <u>Interpharm Press</u>, 2000, J. Kreuter, ed., "Colloidal Drug Delivery Systems," <u>Marcel Dekker, Inc.</u>, 1994, and D.L. Wise, ed., "Flandbook of Pharmaceutical Controlled Release Technolgy," <u>Marcel Dekker, Inc.</u>, 2000. Should the Examiner require a copy of these books, one will be supplied upon request.

In accordance with 37 C.F.R. §1.98(a)(3)(i), a concise explanation of the non-English references are incorporated within the specification.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references. Please charge our Credit Card in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). Credit Card Payment Form SB-2038, with a signature from an authorized cardholder, is enclosed. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-2228, under Order No. 022290.0122PTUS.

Dated: April 17, 2008

Respectfully submitted.

Lacy L. Kolo Registration No.: 55,340

PATTON BOGGS LLP 8484 Westpark Drive, 9th Floor McLean, Virginia 22102 (703) 744-8000

(703) 744-8001 (Fax) Attorney for Applicant